ALK and non-small cell lung carcinoma: In addition, the risk of developing high-grade AST increase (fix effect) was 11.54 (95% CI, 4.33–30.7; p < 0.001, Figure 5B) in advanced NSCLC patients treated with ALK-TKIs in comparison with chemotherapy.